Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 18.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 29.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 12.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 15.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Offi |
Stammdaten
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Unternehmen & Branche
| Name | ROCKWELL MEDICAL, INC. |
|---|---|
| Ticker | RMTI |
| CIK | 0001041024 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 35,3 Mio. USD |
| Beta | 1,71 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -5,314,000 | -0.15 | 57,145,000 | 36,981,000 | |
| 2025-09-30 | 10-Q | -1,753,000 | -0.05 | 57,486,000 | 37,020,000 | |
| 2025-06-30 | 10-Q | -1,492,000 | -0.05 | 52,625,000 | 30,409,000 | |
| 2025-03-31 | 10-Q | -1,515,000 | -0.04 | 53,961,000 | 31,522,000 | |
| 2024-12-31 | 10-K | -480,000 | -0.03 | 59,208,000 | 32,586,000 | |
| 2024-09-30 | 10-Q | 1,664,000 | 0.04 | 57,084,000 | 29,135,000 | |
| 2024-06-30 | 10-Q | 343,000 | 0.01 | 53,028,000 | 23,498,000 | |
| 2024-03-31 | 10-Q | -1,731,000 | -0.06 | 50,723,000 | 20,643,000 | |
| 2023-12-31 | 10-K | -8,439,000 | -0.37 | 52,173,000 | 21,291,000 | |
| 2023-09-30 | 10-Q | -1,872,000 | -0.07 | 52,606,000 | 21,518,000 | |
| 2023-06-30 | 10-Q | -3,305,000 | -0.18 | 38,037,000 | 9,528,000 | |
| 2023-03-31 | 10-Q | -1,750,000 | -0.10 | 40,472,000 | 12,542,000 | |
| 2022-12-31 | 10-K | -18,679,000 | -1.31 | 46,635,000 | 14,106,000 | |
| 2022-09-30 | 10-Q | -4,190,000 | -0.23 | 54,186,000 | 16,136,000 | |
| 2022-06-30 | 10-Q | -4,967,000 | -0.43 | 59,116,000 | 20,145,000 | |
| 2022-03-31 | 10-Q | -7,162,000 | -0.84 | 37,436,000 | -4,807,000 | |
| 2021-12-31 | 10-K | -32,674,000 | -3.83 | 48,574,000 | 2,535,000 | |
| 2021-09-30 | 10-Q | -7,581,000 | -0.89 | 58,699,000 | 11,094,000 | |
| 2021-06-30 | 10-Q | -8,400,000 | -0.99 | 63,684,000 | 18,203,000 | |
| 2021-03-31 | 10-Q | -7,752,000 | -0.91 | 69,449,000 | 26,178,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-02 | Neri Jesse | Officer, SVP and CFO | Open Market Sale | -886 | 0.84 | -740.25 | -24,2% | |
| 2026-01-02 | Hunter Heather | Officer, Chief Operating Officer | Open Market Sale | -2,868 | 0.84 | -2,396.21 | -78,2% | |
| 2025-10-01 | Neri Jesse | Officer, SVP and CFO | Open Market Sale | -886 | 1.19 | -1,054.34 | -34,4% | |
| 2025-10-01 | Strobeck Mark | Director, Officer, President and CEO | Open Market Sale | -6,926 | 1.19 | -8,241.94 | -269,0% | |
| 2025-10-01 | Chole Timothy | Officer, SVP and CCO | Open Market Sale | -2,868 | 1.19 | -3,412.92 | -111,4% | |
| 2025-10-01 | Hunter Heather | Officer, SVP, Chief Operating Officer | Open Market Sale | -2,868 | 1.19 | -3,412.92 | -111,4% | |
| 2025-07-01 | Strobeck Mark | Director, Officer, President and CEO | Open Market Sale | -6,926 | 0.82 | -5,679.32 | -185,3% | |
| 2025-07-01 | Neri Jesse | Officer, SVP and CFO | Open Market Sale | -886 | 0.82 | -726.52 | -23,7% | |
| 2025-07-01 | Chole Timothy | Officer, SVP and CCO | Open Market Sale | -2,868 | 0.82 | -2,351.76 | -76,7% | |
| 2025-07-01 | Strobeck Mark | Director, Officer, President and CEO | Open Market Sale | -6,926 | 0.82 | -5,679.32 | -185,3% | |
| 2025-07-01 | Chole Timothy | Officer, SVP and CCO | Open Market Sale | -2,868 | 0.82 | -2,351.76 | -76,7% | |
| 2025-07-01 | Neri Jesse | Officer, SVP and CFO | Open Market Sale | -886 | 0.82 | -726.52 | -23,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.